Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.2
4.6
Journals
Bioengineering
Special Issues
Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine
share announcement

Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine

A special issue of Bioengineering (ISSN 2306-5354). This special issue belongs to the section "Regenerative Engineering".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 3535

Special Issue Editors

Dr. Moritz Benjamin Immohr

E-Mail Website
Guest Editor
Department of Thoracic and Cardiovascular Surgery, Medical Faculty and University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany
Interests: tissue engineering; 3D-bioprinting; regenerative medicine; biomaterials; artificial organs; cardiac surgery; cardiology
Dr. Elvira Weber

E-Mail Website
Guest Editor
Department of Cardiac Surgery, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, 40225 Düsseldorf, Germany
Interests: adipose tissue organoids; cardioids; immunometabolism; macrophages; adipoids and tissue engineering

Special Issue Information

Dear Colleagues,

Cardiovascular pathologies are one of the leading global causes of disease burden. Especially myocardial ischemia, heart valve pathologies, and heart failure still demand novel patient-tailored treatment innovations. Tissue engineering and regenerative medicine cover a broad field that can advance our current understanding of both the pathogenesis and the therapy of cardiovascular diseases. This special issue of Bioengineering will focus on Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine and aims at high-quality research addressing current challenges in this field. Topics of interest cover both disease modelling and therapy innovations and include but are not limited to bioengineering with bioprinting and biomaterials, tissue decellularization and repopulation, stem cell research and cell therapy, 3D-cell culture and organoids as well as xenotransplantation and artificial organs.

We invite researchers to contribute to this special issue with their work addressing current challenges and innovations in the field of cardiovascular medicine, especially methodical articles on myocardial injury, valvular pathologies, vascular biology, and the development of new cardiovascular implants.

Dr. Moritz Benjamin Immohr
Dr. Elvira Weber
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Bioengineering is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tissue engineering
  • 3D-bioprinting
  • biomaterials
  • organoids
  • cell therapy
  • myocardial injury
  • valvular pathologies
  • vascular biology

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

19 pages, 9511 KiB  
Article
Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification
by Wenpeng Yu, Xiaowei Zhu, Jichun Liu and Jianliang Zhou
Bioengineering 2023, 10(7), 859; https://doi.org/10.3390/bioengineering10070859 - 20 Jul 2023
Cited by 2 | Viewed by 1307
Abstract
The goal of tissue-engineered heart valves (TEHV) is to replace normal heart valves and overcome the shortcomings of heart valve replacement commonly used in clinical practice. However, calcification of TEHV is the major bottleneck to break for both clinical workers and researchers. Endothelialization [...] Read more.
The goal of tissue-engineered heart valves (TEHV) is to replace normal heart valves and overcome the shortcomings of heart valve replacement commonly used in clinical practice. However, calcification of TEHV is the major bottleneck to break for both clinical workers and researchers. Endothelialization of TEHV plays a crucial role in delaying valve calcification by reducing platelet adhesion and covering the calcified spots. In the present study, we loaded RunX2-siRNA and VEGF into mesoporous silica nanoparticles and investigated the properties of anti-calcification and endothelialization in vitro. Then, the mesoporous silica nanoparticle was immobilized on the decellularized porcine aortic valve (DPAV) by layer self-assembly and investigated the anti-calcification and endothelialization. Our results demonstrated that the mesoporous silica nanoparticles delivery vehicle demonstrated good biocompatibility, and a stable release of RunX2-siRNA and VEGF. The hybrid decellularized valve exhibited a low hemolysis rate and promoted endothelial cell proliferation and adhesion while silencing RunX2 gene expression in valve interstitial cells, and the hybrid decellularized valve showed good mechanical properties. Finally, the in vivo experiment showed that the mesoporous silica nanoparticles delivery vehicle could enhance the endothelialization of the hybrid valve. In summary, we constructed a delivery system based on mesoporous silica to biofunctionalized TEHV scaffold for endothelialization and anti-calcification. Full article
(This article belongs to the Special Issue Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine)
►▼ Show Figures

Graphical abstract

16 pages, 11145 KiB  
Article
Three-Dimensional Bioprinting of Ovine Aortic Valve Endothelial and Interstitial Cells for the Development of Multicellular Tissue Engineered Tissue Constructs
by Moritz Benjamin Immohr, Helena Lauren Teichert, Fabió dos Santos Adrego, Vera Schmidt, Yukiharu Sugimura, Sebastian Johannes Bauer, Mareike Barth, Artur Lichtenberg and Payam Akhyari
Bioengineering 2023, 10(7), 787; https://doi.org/10.3390/bioengineering10070787 - 30 Jun 2023
Cited by 1 | Viewed by 1111
Abstract
To investigate the pathogenic mechanisms of calcified aortic valve disease (CAVD), it is necessary to develop a new three-dimensional model that contains valvular interstitial cells (VIC) and valvular endothelial cells (VEC). For this purpose, ovine aortic valves were processed to isolate VIC and [...] Read more.
To investigate the pathogenic mechanisms of calcified aortic valve disease (CAVD), it is necessary to develop a new three-dimensional model that contains valvular interstitial cells (VIC) and valvular endothelial cells (VEC). For this purpose, ovine aortic valves were processed to isolate VIC and VEC that were dissolved in an alginate/gelatin hydrogel. A 3D-bioprinter (3D-Bioplotter® Developer Series, EnvisionTec, Gladbeck, Germany) was used to print cell-laden tissue constructs containing VIC and VEC which were cultured for up to 21 days. The 3D-architecture, the composition of the culture medium, and the hydrogels were modified, and cell viability was assessed. The composition of the culture medium directly affected the cell viability of the multicellular tissue constructs. Co-culture of VIC and VEC with a mixture of 70% valvular interstitial cell and 30% valvular endothelial cell medium components reached the cell viability best tested with about 60% more living cells compared to pure valvular interstitial cell medium (p = 0.02). The tissue constructs retained comparable cell viability after 21 days (p = 0.90) with different 3D-architectures, including a “sandwich” and a “tube” design. Good long-term cell viability was confirmed even for thick multilayer multicellular tissue constructs. The 3D-bioprinting of multicellular tissue constructs with VEC and VIC is a successful new technique to design tissue constructs that mimic the structure of the native aortic valve for research applications of aortic valve pathologies. Full article
(This article belongs to the Special Issue Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine)
►▼ Show Figures

Graphical abstract

Review

Jump to: Research

19 pages, 1122 KiB  
Review
Endothelial Reprogramming in Atherosclerosis
by Lu Zhang, Xin Wu and Liang Hong
Bioengineering 2024, 11(4), 325; https://doi.org/10.3390/bioengineering11040325 - 27 Mar 2024
Viewed by 493
Abstract
Atherosclerosis (AS) is a severe vascular disease that results in millions of cases of mortality each year. The development of atherosclerosis is associated with vascular structural lesions, characterized by the accumulation of immune cells, mesenchymal cells, lipids, and an extracellular matrix at the [...] Read more.
Atherosclerosis (AS) is a severe vascular disease that results in millions of cases of mortality each year. The development of atherosclerosis is associated with vascular structural lesions, characterized by the accumulation of immune cells, mesenchymal cells, lipids, and an extracellular matrix at the intimal resulting in the formation of an atheromatous plaque. AS involves complex interactions among various cell types, including macrophages, endothelial cells (ECs), and smooth muscle cells (SMCs). Endothelial dysfunction plays an essential role in the initiation and progression of AS. Endothelial dysfunction can encompass a constellation of various non-adaptive dynamic alterations of biology and function, termed “endothelial reprogramming”. This phenomenon involves transitioning from a quiescent, anti-inflammatory state to a pro-inflammatory and proatherogenic state and alterations in endothelial cell identity, such as endothelial to mesenchymal transition (EndMT) and endothelial-to-immune cell-like transition (EndIT). Targeting these processes to restore endothelial balance and prevent cell identity shifts, alongside modulating epigenetic factors, can attenuate atherosclerosis progression. In the present review, we discuss the role of endothelial cells in AS and summarize studies in endothelial reprogramming associated with the pathogenesis of AS. Full article
(This article belongs to the Special Issue Recent Progress in Cardiovascular Tissue Engineering and Regenerative Medicine)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop